Abstract B143: Lace molecular vaccine with adjuvant booster to enhance immunogenicity

Abstract

Abstract Manipulation of vaccine adjuvants, including bioconjugation and particle formulation, is a prevailing approach to achieve efficient delivery and improve therapeutic efficacy. However, these approaches may compromise bioactivity or may not be desirable when these compounds are chemically or physically unmanipulable. Here, we report an “adjuvant booster” strategy to markedly promote immunogenicity by simply lacing molecular vaccines with an adjuvant booster. We created an adjuvant booster, lipid modified 20-mer thymidine oligodeoxynucleotide (lipo T20), which could significantly increase the potency of Toll-like receptor 7 (TLR7) ligands in both murine and human TLR7 HEK 293 cells and substantially target draining lymph nodes where unmodified adjuvant rarely accumulated. Subcutaneous administration of “imiquimod/protein antigen” vaccine laced with lipo T20 in mice resulted in a five-fold increase in T-cell priming and enhanced antibody response in comparison to booster-free vaccine. “Adjuvant booster” strategy provides an alternative and simple methodology to further enhance immunogenicity of molecular vaccines. Citation Format: Chunson Yu, Haipeng Liu. Lace molecular vaccine with adjuvant booster to enhance immunogenicity [abstract]. In: Proceedings of the Fourth CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference: Translating Science into Survival; Sept 30-Oct 3, 2018; New York, NY. Philadelphia (PA): AACR; Cancer Immunol Res 2019;7(2 Suppl):Abstract nr B143.